FDA Approves Bristol Myers Squibb’s Sotyktu for Treatment of Active Psoriatic Arthritis

 The U.S. Food and Drug Administration (FDA) has approved Bristol Myers Squibb’s Sotyktu® (deucravacitinib) for the treatment of adults with active psoriatic arthritis. This decision marks a significant regulatory milestone for the medication, which is now authorized for use in addressing this chronic inflammatory condition that affects joints and skin.

Sotyktu® is an oral, selective tyrosine kinase 2 (TYK2) inhibitor designed to target specific pathways involved in inflammation. The FDA approval follows clinical trials that evaluated its safety and efficacy in patients with active psoriatic arthritis. The trials demonstrated improvements in joint symptoms, skin lesions, and overall disease activity compared to placebo groups. Psoriatic arthritis is a complex autoimmune disease that can lead to joint damage if untreated, affecting approximately 1-2% of the population globally.

https://www.geneonline.com/fda-approves-bristol-myers-squibbs-sotyktu-for-treatment-of-active-psoriatic-arthritis/